Skip to main content

Obesity and poor sleep are risk factors for developing dementia

From Kevin Boyd

Is it not interesting that obesity, and its associated comorbidities, are associated with a higher lifetime prevalence of all-cause dementia? However, is it obesity that is a causal factor or the fact that obesity is strongly associated with (1) reduced exercise and a sedentary lifestyle, (2) hypertension and metabolic syndrome (insulin resistance), (3) systemic inflammatory syndrome, (4) mental health problems (depression/anxiety) and (5) sleep apnoea and other sleep disorders? All five of these factors may be the causal factor and not necessarily obesity itself.

The modern epidemic of obesity is been driven largely by a change in our diets in particularly the ubiquitous consumption of processed and ultra-processed foods and the large increase in sugar (sucrose) consumption. Prior to the Victorian era, sugar was not a dietary staple and we tended to eat large quantities of unprocessed foods. Eating unprocessed foods meant we had to work hard at chewing food, which created the stimulus for our mandibles and faces to develop. Eating processed foods means our mandibles and face have gotten smaller and has resulted in an epidemic of malocclusion and impacted wisdom teeth. This also resulted in our tongues being too big for our smaller mouths and this has resulted in our nasopharyngeal space becoming relatively smaller. The result of all of this is that obstructive sleep apnoea (OSA) is now commonly seen in children with malocclusion syndromes.

This is important because OSA results in the brain becoming intermittently hypoxic and disrupted sleep us affecting the normal physiology of the brain. We need good quality sleep to consolidate memories and for the glymphatic system to clear away the intracellular debris. Poor sleep quality is creating the substrate for an unhealthy brain from a very young age and unhealthy brains are primed to degenerate faster and earlier and may be contributing to the rise in all-cause dementia.

The anatomical changes in the mandible and face underlying the rising incidence of sleep apnoea is not the only factor affecting sleep quality at a population level. Light and noise pollution, screen addiction and many other factors are affecting sleep quality at a population level. I am therefore proposing that we need to look into sleep deprivation at a population level as an important modifiable risk factor for all-cause dementia. The question is how do we go about doing this?


Picture from Kevin Boyd

 
CoI: multiple

Twitter: @gavinGiovannoni                                                     Medium: @gavin_24211

Comments

Popular posts from this blog

Moved to substack

Dear Reader We have moved the preventive neurology unit blog to a new platform called substack . Google is discontinuing its Feedburner and has not added many new features to blogger for some time, which is why we have decided to move the site.  https://preventiveneurology.substack.com/  Thanks Gavin Giovannoni

Are you ready for an EBV vaccine to prevent MS?

"Professor Giovannoni, you tell me that my daughter has a 1 in 40 chance of developing multiple sclerosis and that MS has reached epidemic proportions in parts of the world? Is there anything I can do to reduce her chances of getting MS? Is there anything we can do to stop other people from getting MS?" Although multiple sclerosis (MS) is a complex disease due to the interaction of genetic and environmental factors data on the occurrence of MS at the population level (epidemiology) supports the Epstein Barr Virus (EBV) as being necessary, but not sufficient, for someone to develop MS. In other words, EBV is probably the cause of MS. Of all the putative causative agents that have been proposed to be associated with MS, EBV is the only one where the risk of getting MS if you are EBV negative is close to zero or zero if you limit the analyses to those studies which use a technique called immunofluorescence microscopy as the gold-standard assay to detect anti-EBV antibodies. EBV

The Aducanumab shitstorm

Congratulations to  Al Sandrock , from Biogen, for never giving up on science and for being a  risk-taker extraordinaire .   Photo by Markus Winkler on Unsplash The FDA’s controversial approval of aducanumab for the treatment of Alzheimer’s disease on Monday has caused a shitstorm. The main reason is that in November the FDA’s independent advisory committee voted against recommending approval; they said the data failed to demonstrate persuasively that aducanumab slowed cognitive decline. In a NY Times article Dr Lon Schneider, director of the California Alzheimer’s Disease Center at the University of Southern California and one of the aducanumab site investigators said “This should not be approved, because substantial evidence of effectiveness hasn’t been shown and there’s very little potential that this will address the needs of patients.” What the FDA has done is use the so-called Accelerated Approval Pathway , which allows them to approve a drug for a serious or life-threatening